(NEOG) Neogen - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 1.783m USD | Total Return: 30.5% in 12m

Diagnostic Kits, Veterinary Instruments, Genomics Services, Animal Care
Total Rating 38
Safety 39
Buy Signal -0.37
Medical Devices
Industry Rotation: -0.4
Market Cap: 1.78B
Avg Turnover: 18.8M
Risk 3d forecast
Volatility51.5%
VaR 5th Pctl8.36%
VaR vs Median-1.69%
Reward TTM
Sharpe Ratio0.66
Rel. Str. IBD68.3
Rel. Str. Peer Group67.4
Character TTM
Beta1.526
Beta Downside2.053
Hurst Exponent0.449
Drawdowns 3y
Max DD81.59%
CAGR/Max DD-0.25
CAGR/Mean DD-0.44
EPS (Earnings per Share) EPS (Earnings per Share) of NEOG over the last years for every Quarter: "2021-05": 0.15, "2021-08": 0.16, "2021-11": 0.1, "2022-02": 0.05, "2022-05": 0.14, "2022-08": 0.05, "2022-11": -0.19, "2023-02": 0.04, "2023-05": 0.14, "2023-08": 0.11, "2023-11": 0.11, "2024-02": 0.12, "2024-05": 0.1, "2024-08": 0.07, "2024-11": 0.11, "2025-02": 0.1, "2025-05": 0.05, "2025-08": 0.04, "2025-11": 0.1, "2026-02": 0.09,
EPS CAGR: -11.11%
EPS Trend: 19.0%
Last SUE: 0.72
Qual. Beats: 0
Revenue Revenue of NEOG over the last years for every Quarter: 2021-05: 127.425, 2021-08: 128.305, 2021-11: 130.517, 2022-02: 128.244, 2022-05: 140.093, 2022-08: 132.348999, 2022-11: 230.033, 2023-02: 218.255, 2023-05: 241.81, 2023-08: 228.987, 2023-11: 229.629, 2024-02: 228.812, 2024-05: 236.794, 2024-08: 216.964, 2024-11: 231.258, 2025-02: 220.98, 2025-05: 225.459, 2025-08: 209.189, 2025-11: 224.691, 2026-02: 211.2,
Rev. CAGR: 11.57%
Rev. Trend: 46.5%
Last SUE: 1.03
Qual. Beats: 3

Warnings

Interest Coverage Ratio -9.0 is critical

Altman Z'' -1.11 < 1.0 - financial distress zone

Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: NEOG Neogen

Neogen Corporation (NASDAQ: NEOG) specializes in food and animal safety solutions through two primary operating segments. The Food Safety division provides diagnostic kits, software, and laboratory services to detect pathogens, allergens, and toxins throughout the global agricultural supply chain. The Animal Safety division focuses on veterinary instruments, genomics services, and biosecurity products, such as disinfectants and rodenticides, for livestock and companion animal markets.

The company operates within the broader life sciences and agricultural technology sectors, where demand is driven by increasingly stringent global food safety regulations and the industrialization of protein production. Neogen’s business model relies on a mix of recurring revenue from consumable diagnostic tests and high-value genomic data services used by breeders to improve livestock traits. Investors may find it useful to examine detailed valuation metrics on ValueRay to better understand the companys market position.

Headquartered in Lansing, Michigan, Neogen serves a diverse client base ranging from grain millers and seafood processors to veterinary clinics and government agencies. This diversified exposure helps mitigate risks associated with specific commodity cycles or regional agricultural downturns.

Headlines to Watch Out For
  • 3M Food Safety merger integration costs and synergy realization timelines
  • Global food pathogen testing demand across grain and dairy markets
  • Livestock genomics adoption rates and companion animal veterinary spending
  • Raw material inflation and supply chain volatility impacting gross margins
  • Regulatory shifts in global food safety standards driving diagnostic kit sales
Piotroski VR‑10 (Strict) 1.5
Net Income: -608.8m TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA 2.34 > 1.0
NWC/Revenue: 50.47% < 20% (prev 45.31%; Δ 5.16% < -1%)
CFO/TA 0.02 > 3% & CFO 69.5m > Net Income -608.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.92 > 1.5 & < 3
Outstanding Shares: last quarter (217.7m) vs 12m ago 0.31% < -2%
Gross Margin: 39.86% > 18% (prev 0.42%; Δ 3.94k% > 0.5%)
Asset Turnover: 23.54% > 50% (prev 22.45%; Δ 1.10% > 0%)
Interest Coverage Ratio: -9.03 > 6 (EBITDA TTM -445.5m / Interest Expense TTM 62.3m)
Altman Z'' -1.11
A: 0.13 (Total Current Assets 590.0m - Total Current Liabilities 150.6m) / Total Assets 3.36b
B: -0.16 (Retained Earnings -533.0m / Total Assets 3.36b)
C: -0.15 (EBIT TTM -562.6m / Avg Total Assets 3.70b)
D: -0.41 (Book Value of Equity -510.7m / Total Liabilities 1.26b)
Altman-Z'' Score: -1.11 = CCC
Beneish M -3.36
DSRI: 0.89 (Receivables 137.1m/160.1m, Revenue 870.5m/906.0m)
GMI: 1.04 (GM 39.86% / 41.57%)
AQI: 0.93 (AQ_t 0.72 / AQ_t-1 0.78)
SGI: 0.96 (Revenue 870.5m / 906.0m)
TATA: -0.20 (NI -608.8m - CFO 69.5m) / TA 3.36b)
Beneish M-Score: -3.36 (Cap -4..+1) = AA
What is the price of NEOG shares? As of May 20, 2026, the stock is trading at USD 8.35 with a total of 2,922,122 shares traded.
Over the past week, the price has changed by -3.02%, over one month by -13.29%, over three months by -23.95% and over the past year by +30.47%.
Is NEOG a buy, sell or hold? Neogen has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy NEOG.
  • StrongBuy: 2
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the NEOG price?
Analysts Target Price 12 43.7%
Neogen (NEOG) - Fundamental Data Overview as of 18 May 2026
P/E Forward = 16.0
P/S = 2.0478
P/B = 0.937
P/EG = 0.6575
Revenue TTM = 870.5m USD
EBIT TTM = -562.6m USD
EBITDA TTM = -445.5m USD
Long Term Debt = 793.3m USD (from longTermDebt, last quarter)
Short Term Debt = 27.4m USD (from shortTermDebt, last fiscal year)
Debt = 912.6m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 752.7m USD (recalculated: Debt 912.6m - CCE 159.9m)
Enterprise Value = 2.54b USD (1.78b + Debt 912.6m - CCE 159.9m)
Interest Coverage Ratio = -9.03 (Ebit TTM -562.6m / Interest Expense TTM 62.3m)
EV/FCF = 60.69x (Enterprise Value 2.54b / FCF TTM 41.8m)
FCF Yield = 1.65% (FCF TTM 41.8m / Enterprise Value 2.54b)
FCF Margin = 4.80% (FCF TTM 41.8m / Revenue TTM 870.5m)
Net Margin = -69.93% (Net Income TTM -608.8m / Revenue TTM 870.5m)
Gross Margin = 39.86% ((Revenue TTM 870.5m - Cost of Revenue TTM 523.5m) / Revenue TTM)
Gross Margin QoQ = 46.88% (prev 47.48%)
Tobins Q-Ratio = 0.75 (Enterprise Value 2.54b / Total Assets 3.36b)
Interest Expense / Debt = 1.52% (Interest Expense 13.9m / Debt 912.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -444.5m (EBIT -562.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.92 (Total Current Assets 590.0m / Total Current Liabilities 150.6m)
Debt / Equity = 0.43 (Debt 912.6m / totalStockholderEquity, last quarter 2.10b)
 Debt / EBITDA = -1.69 (negative EBITDA) (Net Debt 752.7m / EBITDA -445.5m)
 Debt / FCF = 18.02 (Net Debt 752.7m / FCF TTM 41.8m)
Total Stockholder Equity = 2.10b (last 4 quarters mean from totalStockholderEquity)
RoA = -16.46% (Net Income -608.8m / Total Assets 3.36b)
RoE = -29.00% (Net Income TTM -608.8m / Total Stockholder Equity 2.10b)
RoCE = -19.45% (EBIT -562.6m / Capital Employed (Equity 2.10b + L.T.Debt 793.3m))
 RoIC = -15.24% (negative operating profit) (NOPAT -444.5m / Invested Capital 2.92b)
 WACC = 7.91% (E(1.78b)/V(2.70b) * Re(11.35%) + D(912.6m)/V(2.70b) * Rd(1.52%) * (1-Tc(0.21)))
Discount Rate = 11.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 0.26%
[DCF] Terminal Value 71.09% ; FCFF base≈41.8m ; Y1≈27.4m ; Y5≈12.5m
 [DCF] Fair Price = N/A (negative equity: EV 252.7m - Net Debt 752.7m = -500.0m; debt exceeds intrinsic value)
 EPS Correlation: 18.99 | EPS CAGR: -11.11% | SUE: 0.72 | # QB: 0
Revenue Correlation: 46.48 | Revenue CAGR: 11.57% | SUE: 1.03 | # QB: 3
EPS next Quarter (2026-08-31): EPS=0.04 | Chg30d=-18.18% | Revisions=-20% | Analysts=2
EPS current Year (2026-05-31): EPS=0.37 | Chg30d=+3.73% | Revisions=+14% | GrowthEPS=+12.1% | GrowthRev=-4.2%
EPS next Year (2027-05-31): EPS=0.30 | Chg30d=-8.23% | Revisions=-14% | GrowthEPS=-19.8% | GrowthRev=-0.8%
[Analyst] Revisions Ratio: -20%